Current Opinion in Cardiology最新文献_第9页

High lipoprotein(a) is a risk factor for peripheral artery disease, abdominal aortic aneurysms, and major adverse limb events. 高脂蛋白（a）是外周动脉疾病、腹主动脉瘤和肢体重大不良事件的危险因素。

IF 2 4区医学

Current Opinion in Cardiology Pub Date : 2024-11-01 Epub Date: 2024-09-11 DOI: 10.1097/HCO.0000000000001168

Peter E Thomas, Signe Vedel-Krogh, Pia R Kamstrup

{"title":"High lipoprotein(a) is a risk factor for peripheral artery disease, abdominal aortic aneurysms, and major adverse limb events.","authors":"Peter E Thomas, Signe Vedel-Krogh, Pia R Kamstrup","doi":"10.1097/HCO.0000000000001168","DOIUrl":"10.1097/HCO.0000000000001168","url":null,"abstract":"Purpose of review: To summarize evidence from recent studies of high lipoprotein(a) as a risk factor for peripheral artery disease (PAD), abdominal aortic aneurysms (AAA), and major adverse limb events (MALE). Additionally, provide clinicians with 10-year absolute risk charts enabling risk prediction of PAD and AAA by lipoprotein(a) levels and conventional risk factors.Recent findings: Numerous studies support high lipoprotein(a) as an independent risk factor for PAD, AAA, and MALE. The strongest evidence is from the Copenhagen General Population Study (CGPS) and the UK Biobank, two large general population-based cohorts. In the CGPS, a 50 mg/dl higher genetically determined lipoprotein(a) associated with hazard ratios of 1.39 (1.24-1.56) for PAD and 1.21 (1.01-1.44) for AAA. Corresponding hazard ratio in the UK Biobank were 1.38 (1.30-1.46) and 1.42 (1.28-1.59). In CGPS participants with levels at least 99th (≥143 mg/dl) vs, less than 50th percentile (≤9 mg/dl), hazard ratios were 2.99 (2.09-4.30) for PAD and 2.22 (1.21-4.07) for AAA, with a corresponding incidence rate ratio for MALE of 3.04 (1.55-5.98) in participants with PAD.Summary: Evidence from both observational and genetic studies support high lipoprotein(a) as a causal risk factor for PAD, AAA, and MALE, and highlight the potential of future lipoprotein(a)-lowering therapy to reduce the substantial morbidity and mortality associated with these diseases.","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":" ","pages":"511-519"},"PeriodicalIF":2.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142362499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Coronary artery bypass grafting in acute coronary syndromes: modern indications and approaches. 急性冠状动脉综合征的冠状动脉旁路移植术：现代适应症和方法。

IF 2 4区医学

Current Opinion in Cardiology Pub Date : 2024-11-01 Epub Date: 2024-09-09 DOI: 10.1097/HCO.0000000000001172

Sigrid Sandner, Alissa Florian, Marc Ruel

{"title":"Coronary artery bypass grafting in acute coronary syndromes: modern indications and approaches.","authors":"Sigrid Sandner, Alissa Florian, Marc Ruel","doi":"10.1097/HCO.0000000000001172","DOIUrl":"10.1097/HCO.0000000000001172","url":null,"abstract":"Purpose of review: Acute coronary syndromes (ACS) are a leading cause of morbidity and mortality worldwide, with approximately 1.2 million hospitalizations annually in the U.S. This review aims to explore the contemporary evidence regarding revascularization strategies, including percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), in ACS patients. It also addresses the unresolved questions concerning the optimal procedural aspects of surgery and antithrombotic therapy for secondary prevention postsurgery.Recent findings: Recent studies highlight that while PCI is generally preferred for its timeliness in high-risk non-ST-elevation ACS (NSTE-ACS) patients, CABG offers a benefit in terms of cardiovascular events in those with multivessel disease, particularly in the presence of diabetes and higher coronary disease complexity. For ST-elevation myocardial infarction (STEMI), CABG is less frequently utilized due to the preference for primary PCI, but it remains crucial for patients with complex anatomy or failed PCI. Furthermore, the optimal timing and type of antiplatelet therapy post-CABG remain controversial, with current evidence supporting the use of dual antiplatelet therapy (DAPT) to reduce ischemic events but necessitating careful management to balance bleeding risks.Summary: In patients with ACS, the choice between PCI and CABG depends on the complexity of coronary disease and patient comorbidities. CABG is particularly beneficial for multivessel disease in NSTE-ACS and specific STEMI cases where PCI is not feasible. The management of antiplatelet therapy postsurgery requires a nuanced approach to minimize bleeding risks while preventing thrombotic complications. Further randomized clinical trials are needed to solidify these findings and guide clinical practice.","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":" ","pages":"485-490"},"PeriodicalIF":2.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From remnant cholesterol to lipoprotein(a) - emerging risk factors for cardiovascular diseases beyond low density lipoprotein: Erratum. 从残余胆固醇到脂蛋白（a）--低密度脂蛋白之外新出现的心血管疾病风险因素：勘误。

IF 2 4区医学

Current Opinion in Cardiology Pub Date : 2024-09-01 Epub Date: 2024-08-08 DOI: 10.1097/01.hco.0001027436.73291.01

引用次数: 0

REVIVED BCIS-2: update and key learnings. 经修订的 BCIS-2：最新情况和主要经验教训。

IF 2 4区医学

Current Opinion in Cardiology Pub Date : 2024-09-01 Epub Date: 2024-08-08 DOI: 10.1097/HCO.0000000000001158

Tesfamariam Aklilu Betemariam, Holly Morgan, Divaka Perera

{"title":"REVIVED BCIS-2: update and key learnings.","authors":"Tesfamariam Aklilu Betemariam, Holly Morgan, Divaka Perera","doi":"10.1097/HCO.0000000000001158","DOIUrl":"10.1097/HCO.0000000000001158","url":null,"abstract":"Purpose of review: This review summarises the shifting paradigms in the treatment of ischemic left ventricular dysfunction, spotlighting the revascularization for ischemic ventricular dysfunction-British cardiovascular intervention society-2 (REVIVED-BCIS2) trial results and its impact on key therapeutic goals: survival, left ventricular function, arrhythmia prevention, quality of life and viability testing.Recent findings: The REVIVED-BCIS2 trial, and its subsequent sub studies highlighted that (PCI) does not provide additional benefits to optimal medical therapy in terms of improving survival, left ventricular (LV) function, arrhythmic risk or quality of life. Additionally, viability testing did not differentiate patients who could benefit from PCI, although scar burden was found to be a significant predictor of outcome in these patients.Summary: The outcomes of REVIVED have challenged multiple existing beliefs in the field of ischaemic left ventricular dysfunction management, emphasising the importance of investigating evidence free areas in our practice. Future work, including the STICH3 international consortium of trials, aims to answer some of the remaining unanswered questions.","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":"39 5","pages":"431-436"},"PeriodicalIF":2.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141898973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nuclear imaging techniques for cardiac amyloidosis. 心脏淀粉样变性的核成像技术。

IF 2 4区医学

Current Opinion in Cardiology Pub Date : 2024-09-01 Epub Date: 2024-07-05 DOI: 10.1097/HCO.0000000000001167

Jean Michel Saad, Mouaz H Al-Mallah

{"title":"Nuclear imaging techniques for cardiac amyloidosis.","authors":"Jean Michel Saad, Mouaz H Al-Mallah","doi":"10.1097/HCO.0000000000001167","DOIUrl":"10.1097/HCO.0000000000001167","url":null,"abstract":"Purpose of review: Cardiac amyloidosis is a condition marked by the misfolding of precursor proteins into insoluble amyloid fibrils, leading to restrictive cardiomyopathy and heart failure symptoms. This review discusses advancements in nuclear imaging techniques that enhance the diagnosis and guide the management of cardiac amyloidosis, addressing the critical need for early and accurate detection in clinical practice.Recent findings: Recent studies and guidelines emphasizes the pivotal role of nuclear imaging techniques in diagnosing cardiac amyloidosis. Cardiac scintigraphy, using bone-avid tracers like 99mTc-PYP, 99mTc-DPD, and 99mTc-HMDP, is instrumental in distinguishing between transthyretin amyloidosis and light chain amyloidosis. PET, with tracers such as 11C-Pittsburgh Compound B (11C-PiB) and 18F-Florbetapir, offers significant potential in measuring amyloid burden and monitoring disease progression, providing detailed insights into the myocardial involvement.Summary: The advancements in nuclear imaging techniques significantly impact the management of cardiac amyloidosis. These methods allow for a more accurate diagnosis, detailed assessment of disease extent, and better differentiation between amyloidosis types, which are crucial for tailoring treatment approaches. The integration of these techniques into clinical practice is essential for improving patient outcomes and advancing research in cardiac amyloidosis.","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":" ","pages":"389-394"},"PeriodicalIF":2.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141536035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Device therapy for heart failure management. 治疗心力衰竭的设备疗法。

IF 2 4区医学

Current Opinion in Cardiology Pub Date : 2024-09-01 Epub Date: 2024-06-27 DOI: 10.1097/HCO.0000000000001165

Fouad Chouairi, Allison Levin, Marat Fudim

{"title":"Device therapy for heart failure management.","authors":"Fouad Chouairi, Allison Levin, Marat Fudim","doi":"10.1097/HCO.0000000000001165","DOIUrl":"10.1097/HCO.0000000000001165","url":null,"abstract":"Purpose of review: Given the prevalence of heart failure (HF) and the interdisciplinary nature of device therapy, it is paramount that cardiologists not only understand the current landscape of goal-directed medical therapy, but also the ongoing efforts in device development. Thus, we aim to provide a practical overview of the broad approaches being utilized in the burgeoning field of device-based therapies for heart failure.Recent findings: Currently, a diverse array of devices for HF treatment is being developed and tested, each targeting distinct aspects of HF pathophysiology. These innovative solutions encompass a wide spectrum, ranging from devices enabling remote monitoring of HF associated physiological parameters, to those focused on creating interatrial shunts and effecting structural modifications of the left ventricle, as well as to those designed to modulate the autonomic nervous system and diaphragm. Notably, a subset of these emerging devices is directed towards treating patients with heart failure with preserved ejection fraction, a population that has traditionally not been served by device-based therapies.Summary: In recent decades, there has been a remarkable surge in the development and utilization of device-based treatments for managing HF. It is important for physicians to be familiar with these devices, their mechanisms of action, and their applications.","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":"39 5","pages":"465-474"},"PeriodicalIF":2.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141898971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Subclinical valve leaflet thrombosis following bioprosthetic aortic valve replacement. 生物人工主动脉瓣置换术后的亚临床瓣叶血栓形成。

IF 2 4区医学

Current Opinion in Cardiology Pub Date : 2024-09-01 Epub Date: 2024-06-19 DOI: 10.1097/HCO.0000000000001161

Carlos Giuliani, Antonela Zanuttini, Erwan Salaun, Nancy Côté, Marie Annick Clavel, Philippe Pibarot

{"title":"Subclinical valve leaflet thrombosis following bioprosthetic aortic valve replacement.","authors":"Carlos Giuliani, Antonela Zanuttini, Erwan Salaun, Nancy Côté, Marie Annick Clavel, Philippe Pibarot","doi":"10.1097/HCO.0000000000001161","DOIUrl":"10.1097/HCO.0000000000001161","url":null,"abstract":"Purpose of review: Subclinical leaflet thrombosis (SLT) is often an incidental finding characterized by a thin layer of thrombus involving one, two or three leaflets, with typical appearance on multi-detector computed tomography (MDCT) of hypo-attenuating defect at the aortic side of the leaflet, also called hypo-attenuating leaflet thickening (HALT). SLT may occur following both transcatheter aortic replacement (TAVR) or biological surgical aortic valve replacement (SAVR). The aim of this review is to present an overview of the current state of knowledge on the incidence, diagnosis, clinical impact, and management of SLT following TAVR or SAVR.Recent findings: SLT occurs in 10-20% of patients following TAVR and is somewhat more frequent than following SAVR (5-15%). SLT may regress spontaneously without treatment in about 50% of the cases but may also progress to clinically significant valve thrombosis in some cases. Oral anticoagulation with vitamin K antagonist is reasonable if SLT is detected by echocardiography and/or MDCT during follow-up and is generally efficient to reverse SLT. SLT is associated with mild increase in the risk of stroke but has no impact on survival. SLT has been linked with accelerated structural valve deterioration and may thus impact valve durability and long-term outcomes.Summary: SLT is often an incidental finding on echocardiography or MDCT that occurs in 10-20% of patients following TAVR or 5-15% following biological SAVR and is associated with a mild increase in the risk of thrombo-embolic event with no significant impact on mortality but may be associated with reduced valve durability.","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":" ","pages":"457-464"},"PeriodicalIF":2.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141428373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vascular regenerative cell content in South Asians: the key learnings. 南亚人的血管再生细胞内容：重要启示。

IF 2 4区医学

Current Opinion in Cardiology Pub Date : 2024-09-01 Epub Date: 2024-06-07 DOI: 10.1097/HCO.0000000000001159

Aishwarya Krishnaraj, Fallon Dennis, Hwee Teoh, Subodh Verma, David A Hess

{"title":"Vascular regenerative cell content in South Asians: the key learnings.","authors":"Aishwarya Krishnaraj, Fallon Dennis, Hwee Teoh, Subodh Verma, David A Hess","doi":"10.1097/HCO.0000000000001159","DOIUrl":"10.1097/HCO.0000000000001159","url":null,"abstract":"Purpose of review: We aim to provide a comprehensive examination of the literature linking elevated rates of cardiovascular disease (CVD) in individuals of South Asian ethnicity with the severity of circulating vascular regenerative cell exhaustion.Recent findings: Recent findings have demonstrated reduced bioavailability of pro-vascular progenitor cell subsets in individuals with T2D and obesity. Depletion of vascular regenerative cells in the bone marrow - coupled with decreased mobilization into circulation - can negatively impact the capacity for vascular repair and exacerbate CVD risk. Several recent studies have established that although South Asian individuals possess similar inflammatory cell burden compared with other ethnicities, they exhibit marked decreases in vessel regenerative hematopoietic progenitor cells and monocyte subsets. Validation of these findings and investigation the functional capacity of vascular regenerative cell subsets to mediate vessel repair is highly warranted.Summary: Vascular regenerative cells play a key role coordinating angiogenic and arteriogenic vessel remodelling. Recent studies have demonstrated that South Asian individuals with T2D show severe depletion in circulating vascular regenerative cell subsets. Because the reversal of vascular regenerative cell exhaustion by current glucose-lowering pharmaceutical agents has recently been documented, early intervention to bolster vascular regenerative cell content may prevent CVD co-morbidities in South Asian individuals with cardiometabolic disease.","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":" ","pages":"444-450"},"PeriodicalIF":2.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141285475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Left main revascularization guidelines: navigating the data. 左主干血管重建指南：数据导航。

IF 2 4区医学

Current Opinion in Cardiology Pub Date : 2024-09-01 Epub Date: 2024-06-20 DOI: 10.1097/HCO.0000000000001160

Aurelien Vallée, Kenza Rahmouni, Menaka Ponnambalam, Hugo Issa, Marc Ruel

引用次数: 0

Cardiac magnetic resonance findings in cardiac amyloidosis. 心脏淀粉样变性的心脏磁共振发现。

IF 2 4区医学

Current Opinion in Cardiology Pub Date : 2024-09-01 Epub Date: 2024-07-15 DOI: 10.1097/HCO.0000000000001166

Aneesh Dhore-Patil, Vivek Modi, El-Moatasem Gabr, Akila Bersali, Amr Darwish, Dipan Shah

{"title":"Cardiac magnetic resonance findings in cardiac amyloidosis.","authors":"Aneesh Dhore-Patil, Vivek Modi, El-Moatasem Gabr, Akila Bersali, Amr Darwish, Dipan Shah","doi":"10.1097/HCO.0000000000001166","DOIUrl":"10.1097/HCO.0000000000001166","url":null,"abstract":"Purpose of review: The purpose of this review is to highlight the increasing importance of cardiac magnetic resonance (CMR) imaging in diagnosing and managing cardiac amyloidosis, especially given the recent advancements in treatment options.Recent findings: This review emphasizes the crucial role of late gadolinium enhancement (LGE) with phase-sensitive inversion recovery (PSIR) techniques in both diagnosing and predicting patient outcomes in cardiac amyloidosis. The review also explores promising new techniques for diagnosing early-stage disease, such as native T1 mapping and ECV quantification. Additionally, it delves into experimental techniques like diffusion tensor imaging, MR elastography, and spectroscopy.Summary: This review underscores CMR as a powerful tool for diagnosing cardiac amyloidosis, assessing risk factors, and monitoring treatment response. While LGE imaging remains the current best practice for diagnosis, emerging techniques such as T1 mapping and ECV quantification offer promise for improved detection, particularly in early stages of the disease. This has significant implications for patient management as newer therapeutic options become available for cardiac amyloidosis.","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":" ","pages":"395-406"},"PeriodicalIF":2.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0